76322-06-0

Basic information

• Product Name: Acetic acid, (2-formyl-5-methoxyphenoxy)-, ethyl ester
• CAS NO: 76322-06-0
• Molecular Formula: C12H14O5
• Molecular Weight: 238.24
• Mol File: 76322-06-0.mol

Chemical Properties

• CAS DataBase Reference: Acetic acid, (2-formyl-5-methoxyphenoxy)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, (2-formyl-5-methoxyphenoxy)-, ethyl ester(76322-06-0)
• EPA Substance Registry System: Acetic acid, (2-formyl-5-methoxyphenoxy)-, ethyl ester(76322-06-0)

Safety Data

• Hazardous Substances Data: 76322-06-0(Hazardous Substances Data)

Upstream product

• 673-22-3 2-Hydroxy-4-methoxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 
• 95-01-2 2,4-Dihydroxybenzaldehyde 

Downstream Products

• 50551-57-0 ethyl 6-methoxybenzo[b]furan-2-carboxylate 
• 856357-86-3 2-(2-formyl-5-methoxyphenoxy)acetic acid 
• 76322-11-7 (2-ethoxycarbonylmethoxy-4-methoxyphenyl)hydroxyacetonitrile 
• 76322-24-2 7-methoxychroman-3-one 
• 115124-43-1 (2-carboxymethoxy-4-methoxy-phenyl)-acetic acid 
• 76322-19-5 ethyl(2-ethoxycarbonylmethoxy-4-methoxyphenyl)acetate 
• 50551-61-6 6-methoxybenzofuran-2-carboxylic acid 
• 13196-11-7 6-hydroxybenzofuran 
• 158073-00-8 2-carboethoxymethoxy-4-methoxybenzyl alcohol 

Relevant articles and documents

An improved and scale-up synthesis of 6-hydroxybenzofuran

An optimized process for the preparation of 6-hydroxybenzofuran is described. This process consists of three steps: the reaction of 2-hydroxy-4-methoxybenzaldehyde with chloroacetic acid, the formation of the 6-methoxybenzofuran in acetic anhydride, and t

Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

A novel series of shikonin-benzo[b]furan derivatives were designed and synthesized as tubulin polymerization inhibitors, and their biological activities were evaluated. Most compounds revealed the comparable anti-proliferation activities against the cancer cell lines to that of shikonin and simultaneously low cytotoxicity to non-cancer cells. Among them, compound 6c displayed powerful anti-cancer activity with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in HT29 cells. Besides, 6c actuated the HT29 cell cycle arrest at G2/M phase, and influenced the expression of the cell-cycle related protein. Moreover, 6c displayed potent inhibition on cell migration and tube formation that contributes to the antiangiogenesis. These results prompt us to consider 6c as a potential tubulin polymerization inhibitor and is worthy for further study.

Rhodium-Catalyzed Intermolecular Cyclopropanation of Benzofurans, Indoles, and Alkenes via Cyclopropene Ring Opening

The generation of metal carbenoids via ring opening of cyclopropenes by transition metals offers a simple entry into highly reactive intermediates. Herein, we describe a diastereoselective intermolecular rhodium-catalyzed cyclopropanation of heterocycles and alkenes using cyclopropenes as carbene precursors with a low loading of a commercially available rhodium catalyst. The reported method is scalable and could be performed with catalyst loadings as low as 0.2 mol %, with no impact to the reaction yield or selectivity.

S1P RECEPTORS MODULATORS AND THEIR USE THEREOF

The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.

ENDOTHELIN RECEPTOR ANTAGONISTS

Indole derivatives of formula (1) wherein the substituents are defined herein are disclosed. The compounds are useful in methods of antagonizing endothelin receptors, treating hypertension, treating renal failure and treating cerebrovascular disease. Pharmaceutical compositions are also disclosed.